Cipla Weakens as Momentum Slips Below Trend Support

remains one of the stronger quality franchises within Indian pharma, with a diversified presence across domestic formulations, respiratory therapies and international markets. The broader pharmaceutical space continues to benefit from defensive earnings characteristics, chronic therapy growth and recurring demand, but stock-specific momentum can still diverge sharply from the sector theme. Technically, Cipla has slipped into a weaker phase after failing to sustain the rebound toward the ₹1,470–1,480 zone. Price is now near ₹1,384 and has moved below both the 20-day average around ₹1,423 and the 50-day average near ₹1,437. The shorter average has also started rolling lower, while price is forming a sequence of lower highs from the recent peak, showing that momentum has shifted back toward sellers. The ₹1,360–1,380 area becomes the immediate support zone, and a sustained break below it can reopen downside risk toward the ₹1,320–1,340 region. On the upside, the first sign of improvement would be a reclaim of ₹1,420, but a stronger trend recovery would need price back above ₹1,440–1,450. For now, the business remains resilient, but the chart is asking for patience.